A Review of the Therapeutic Interventions in the Management of Pruritus Ani

Arifa Siddika*, Shahab Siddiqi

Department of Surgery (Colorectal), Broomfield Hospital, Mid Essex NHS Trust, Chelmsford, UK

*Corresponding author: Ms. Arifa Siddika, Registrar-Colorectal surgery, Broomfield Hospital, Mid Essex NHS Trust, Chelmsford, Essex, CM1 7ET, UK; E-mail: drsiddika@yahoo.com

Received date: November 14, 2016
Accepted date: January 4, 2017
Published date: January 10, 2017


DOI: 10.15436/2381-0858.17.1220

Abstract

Background: Pruritus Ani (PA) is the chronic itch of perianal skin and is poorly understood. There is a knowledge gap in understanding the pathophysiology and management of PA as there has been little research. The literature is sparse and of variable quality. There have been recent studies in understanding pruritic processing. We have performed a critical review of the literature concerning therapeutic inventions with the insights gained from this new understanding. In addition, an overview of PA is presented.

Method: A systematic review in accordance with Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) guidelines was undertaken. With the heterogeneity of the reviewed studies it was not possible to perform a true systematic review, but a critical appraisal has been performed using the same methodology.

Results: There are five randomised trials, one controlled study, one observational study, and eight case series critically appraised. The studies concerning topical and injectable intradermal steroid, topical tacrolimus and topical capsaicin have not provided evidence for their therapeutic benefit. Studies suggest methylene blue anal tattooing may beneficial in the treatment of PA.

Conclusions: The aim of this paper was a review of the best evidence available on the current treatment of PA. We set up to perform a systematic review, but were unable to due to the heterogeneity of evidence; hence a critical review was performed. There remains an evidence gap in the pathophysiology and treatment of PA. More research is needed, but there are so many unknowns about the nature of PA, this will be currently difficult to perform. The understanding of pruritus and pruritic processing is in its infancy. Newer therapies such as tacrolimus and capsaicin have failed to live up to initial promise, although they can be effective in a few. Anal tattooing shows the greatest promise.

Keywords: Pruritus; Itching; Anus; Ani; Anal canal; Tattooing

Introduction

Pruritus Ani (PA) is defined as the chronic intense itch of the perianal skin and is classified as idiopathic when no apparent cause is found. There is no reliable data on the incidence of PA, but the prevalence is reported to be 1% – 5%[1]. PA is four times more likely to occur in men. Studies of the age group most likely to suffer from PA have reported inconsistent results, ranging from the second to sixth decade of life[2]. Most sufferers have a relapsing and remitting course, but some have severe symptoms that have a significant impact on quality of life. PA is one of those symptoms that can be managed by a variety of clinicians, mostly general practitioners, dermatologists and colorectal surgeons. Unfortunately, like irritable bowel syndrome and chronic pain syndromes, there is an underestimation of how significantly PA can affect quality of life. In addition, due to a scientific knowledge gap, many clinicians are not empathetic towards this patient group. At worst, some clinicians consider that patients are in some way to blame for their condition, especially when available therapies have not been successful.
PA has historically been considered a symptom rather than a diagnosis, but the understanding of pruritic processing has developed recently and may challenge this. The limited evidence base has led to multiple theories about how perianal itch was the end result of multiple seemingly unrelated triggers. This evidence base must be interpreted critically. In a recent landmark psychology paper, publication bias was shown to have an even greater impact than previously thought. In this work, 100 studies were reproduced, following the methods used in the original studies as closely as possible. Ninety-five of the original studies, but only a third of the replication studies were reported to have statistically significant results. Even when the data from the original and replication studies were combined, only two thirds yielded statistically significant results. Clinical studies in other fields are probably affected by reproducibility and publication bias to a similar extent. In a field of research as small as PA, publication bias and reproducibility may be even more of a problem, and all published data should be viewed critically.

The aim of this review was to present an overview of PA and its management, to critically appraise the evidence base for therapeutic interventions used in the management of PA. We have also presented the current understanding of pruritic processing and its neuronal pathways, as these have changed considerably and have a bearing on the analysis of the available research.

Methodology

A systematic review in accordance with Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) guidelines was undertaken. A search of indexed citations from MEDLINE, Cochrane library and PUBMED databases was undertaken using the following terms; “Pruritus Ani”, “anal itching”, “anal irritation”, “pruritus AND (anal or anus or ani or ano)”, “itch* AND (anal or anus)” in October 2015. In addition, a “related articles” search, forward citation functions was performed and the references of published articles reviewed. All abstracts were reviewed and the full texts of all potentially relevant papers were considered. Only peer-reviewed publications in the English language were included in the review. Study quality was assessed according to the recommendations of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. Author and year of publication, number of patients within the study, method and treatments of pruritus ani were extracted from each article included in the review.

Literature searches have found only 283 publications involving PA over a 90-year period, with the majority being abstracts, review articles or opinions. Due to heterogeneity of the evidence identified it has not been possible to carry out a formal systematic review (Figure 1). However, the same methodology has been used to produce a critical review of literature on management of PA.

General processing of pruritus

Itch processing is highly complex, but is not fully understood. There are four subtypes of itch, i.e., pruriceptive, neurogenic, neuropathic and psychogenic. Pruriceptive itch is the classical itch caused by dermal sensation and injury, chemical stimulation, dry skin, dermatological conditions, infestations, and histamine release. Neurogenic itch is caused by systemic conditions such as liver disease and renal failure where there is direct activation of higher centres of itch with no abnormality of itch processing. Neuropathic itch results from the pathological activation of itch processing in certain neurological disorders such as peripheral neuropathy, post-herpetic neuralgia, nerve compression and multiple sclerosis. Psychogenic itch may occur with some psychological conditions that involve primary processing of itch.
Pruritic mediators

Many mediators are involved in the processing of itch. Histamine, serine proteases, neuropeptides, neurotrophins and several inflammatory mediators have roles in histamine-dependent and histamine-independent processing of itch, with some having roles in both systems. Inflammatory mediators and neurotrophins initiate peripheral itch sensitisation in histamine-dependent and histamine-independent pruritic pathways; similar to the sensitisation they produce in nociceptive inflammatory hyperalgiesia.

Pruritive receptors

Pruriceptors (itch receptors) are subsets of sensory C-fibres and A-fibres that process both histamine-dependent and histamine-independent itch via diverse neuronal processing pathways. Pain and itch are processed in the dorsal horn and have some interconnection, with pain-processing neurons actively inhibiting itch neurons. This explains why morphine reduces pain and has the side effect of itch. Processing of pain and itch occurs in similar regions of the brain, but with different activation patterns. Further, the cerebral activation patterns found with histamine differ from those of other prurceptors.

The scratch-itch-scratch cycle may arise from serotonin receptors. When an itch is scratched, the ensuing pain results in release of serotonin, which reduces pain. It does this by activating the serotonin 1A receptor in the spinal cord, but also stimulates a co-located receptor for the gastrin-dependent peptide that induces itch, thus completing the scratch-itch-scratch cycle. Studies of drugs targeting these receptors are underway, but the complex nature of the interactions suggests there will be no magic bullet therapy.

Several other receptors are involved in processing of pruritus, including the transient receptor potential (TRP) channels, which have a crucial role in the processing of pain and itch, but research is yet to be translated into clinical benefit. Of note some TRP channels are involved in regulation of the epidermal barrier.

Similar to nociception, there does seem to some pruritic central sensitisation in some individuals with no neurogenic equivalent. Our view of PA being purely a symptom may need to change with this knowledge.

Anorectal disorders

Twenty-five to fifty-five per cent of patients with PA have been reported to have an anorectal disorder. These include haemorrhoids, fistulae, fissures, skin tags, warts, proctitis, neoplasia and rectal prolapse. It is recommended to treat of all co-existing a norect al conditions. Pironne et al. suggested that surgery for benign anorectal conditions can eliminate perianal fungal infection and both measures together reduce pruritus.

Anal seepage and soiling

Any factor that increases occult or overt faecal soiling augments exposure of the perianal skin to pruritogens. Caplan’s skin-patch test on the perineum and arm (using autologous faeces) produced perianal itch in one third of patients with PA and in 53% of subjects without PA. Studies have also found that 41% - 50% of patients with PA had loose stools and at least once-weekly faecal soiling. In an anorectal physiology study of patients with PA, exaggerated recto-anal inhibitory reflexes and earlier faecal incontinence were noted. Coffee lowers anal resting pressures in over 70% of cases. Faecal seepage may also occur after anal surgery or be caused by high-grade internal rectal prolapse.

Perianal infections

The importance of bacterial and fungal infection in PA is unclear. Certain infections certainly need therapy: Dermatophytes, Threadworms, Erythrasma, sexually transmitted diseases. However, previous studies have grown multiple species of fungi and bacteria from perianal skin that were thought to be causative of PA. However, current microbiological thinking suggests commensal dermal bacteria colonisation does not constitute an infection even if the species is pathogenic. The maintenance and healing of skin integrity is the critical step.

Dermatoses and hypersensitivity

All dermatoses can occur in the perineum and may look different from its appearance elsewhere. Psoriasis has been found in 5% - 55% of patients with PA. In lichen sclerosus, the skin appears white, atrophic, wrinkled and histology is diagnostic and is commonly found in the perineum. Perianal Paget’s disease and Bowen’s disease also have associated itch.

Chemicals found in everyday cleansing and therapeutic preparations, including creams, soaps, wet wipes, sanitary towels, toiletry sprays, deodorants and toilet paper dye, along with medications, such as topical glyceryl trinitrate, local anaesthetic preparations and haemorrhoidal medications can sensitise and cause contact dermatitis. Sensitising chemicals have also been found in topical steroid preparations. As up to 20% of patients may have allergens that can be avoided, patients should have skin patch testing with the European baseline series probably in those who have failed conservative measures.

The biocides methyl chloro iso thiazolinone and methyl isothiazolinone may be a major contributor to this. They are water soluble agents found in many personal care products.

Food and medication

Although there have been no controlled trials investigating dietary modification in the treatment of PA, some researchers have suggested reduction of itch within 14 days if a certain food was avoided. Some oral medications such as laxatives, colpermin, colchicine, quinidine, peppermint oil and antibiotics may lead to PA.

Psychological influences

In some cases, PA may be a manifestation of depression or psychological disturbance. Common mood disorders, such as anxiety and stress, and certain personality traits may contribute to PA.

Examination and investigations

A full examination should be performed with inspection of the perineum, proctoscopy and sigmoidoscopy. Fistula-in-ano, fissure-in-ano, haemorrhoids, prolapse (including internal rectal prolapse), skin tags, or warts should be identified. Investigations include a culture swab and scraping of skin for bacteria and fungi respectively. As up to 20% of patients may have allergens that can be avoided, patients who fail con-
servative measures should have skin patch testing with the European baseline series[26]. An examination under anesthesia of the anorectum with a circular anal dilator and perineal skin biopsy may be needed for refractory cases. The circular anal dilator is useful for determining the presence of internal or external rectal prolapse.

Management

The patient should be advised to cease using all chemicals, including creams, soaps, bubble baths and toilet paper, on their perineum and only use water for cleaning[1,21,26]. The patient should consider avoidance of caffeinated drinks and an elimination diet could be trialled. Hypoallergenic detergents can be suggested for laundry purposes. Allergens discovered by skin patch testing should be avoided.

Acute pruritus ani is a marker of faecal seepage and requires immediate cleansing, especially for nocturnal itch, using water alone. The area should be dabbed dry with a towel. Aqueous cream and emollients can be used instead of soap if cleansing is required. Petroleum ointment, Sudocrem® or Cavilon® should be used as a barrier cream after washing[1,21]. Patients who sweat excessively can place cotton tissue on the perineum. There are five randomised trials, one controlled study, and eight case series are summarised in Table 1 and their methodological quality is variable[28-42]. One major issue is that there is no consistent definition of idiopathic PA.

Table 1: Review of Evidence.

<table>
<thead>
<tr>
<th>Study author, year (citation)</th>
<th>Study type</th>
<th>Clinical condition/ population (n=)</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes/measures</th>
<th>Results</th>
<th>Author conclusions</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al-Ghaniem et al. 2007</td>
<td>Randomised, double blind placebo-controlled crossover pilot trial</td>
<td>Adults (&gt;18 yrs) with idiopathic pruritus ani. n=11 (n=10 completed) Special clinic run by a surgeon and a dermatologist. UK</td>
<td>1% hydrocortisone ointment + advice on hygiene Twice daily for two weeks. 2 weeks’ run-in period 2 weeks’ treatment/placebo 2 weeks’ washout period 2 weeks’ treatment/placebo</td>
<td>Placebo ointment + advice on hygiene</td>
<td>Symptoms Large significant reduction (68%) in the severity of the itch with hydrocortisone compared with placebo (mean difference 19.7 mm, 95% CI 7 to 32.4, p=0.019). (primary outcome; 100 mm visual analogue scale (VAS)) QoL: Large (75%) but non-significant improvement in QoL with hydrocortisone compared with placebo (mean difference in reduction in Dermatology Life Quality Index score: 1.8, 95% CI 0.2 to 3.4, p=0.065). (Secondary outcome) Safety: No side effects were reported Other: Large and significant improvement in clinical appearance of the perianal skin measured by the Eczema Area and Severity Index (EASI). Reduction in the EASI score by a median of 2, range 1-5, p&lt;0.01. (Secondary outcome)</td>
<td>This study demonstrated that 1% hydrocortisone ointment is an effective and safe treatment for PA in the short term.</td>
<td>Small sample size. No power calculations were done as this was a pilot study. The study design did not allow for assessment of the long term effects.</td>
<td></td>
</tr>
<tr>
<td>Author(s)</td>
<td>Case Series/Type</td>
<td>Subjects/Methods</td>
<td>Outcomes/Results</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------------------------------</td>
<td>-------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Siddika, A., et al.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Botterill and Sagar 2002</td>
<td>Case series</td>
<td>Adults (&gt;18 yrs) with chronic pruritus ani who failed to respond to standard primary, dermatological and colorectal care. n=25 (consecutive patients) UK</td>
<td>Pruritus ani and chronic anal fissure having concomitant hypertrophied anal papillae or fibrous anal polyps n=136 India</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Intradermal injection 20 ml solution comprising 15 ml of 1% lignocaine hydrochloride, 5 ml of 1% methylene blue and 100 mg of hydrocortisone. Clinic review at 2 and 6 weeks post-treatment. Annual follow up by phone or at clinic if patients relapsed. Median follow up 11 months (2-25 months).</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Symptoms: 16 patients (64%) were symptom free after one injection. 8 patients were symptom free after second injection (88% of total number). 3 patients (12%) did not respond to treatment (i.e. continued to experience symptoms). QoL: Not assessed. Safety: 1 patient (4%) had short term complications (facial seepage for 2 days after injection).</td>
<td>Intradermal injection of methylene blue in combination with lignocaine and hydrocortisone can provide sustained relief from symptoms in people who fail to respond to standard treatments.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The lack of a comparator group reduces ability to determine to what extent improvements may have occurred without treatment. The study did not report clearly how the outcomes were assessed, or assess severity of symptoms.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gupta 2005</td>
<td>Case series (based on abstract)</td>
<td>People with pruritus ani and chronic anal fissure having concomitant hypertrophied anal papillae or fibrous anal polyps n=136 India</td>
<td>Surgical procedure involving sphincterotomy and destroying of polyps or papillae using a radio frequency device. Follow up: 1 and 18 months</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Symptoms: At one month, there was significant reduction in pruritus (p=0.0003), discharge per anus (p=0.0006), crawling sensation in the anus (p=0.0004) and that of incomplete evacuation (p=0.001). At 18 months follow up, 9% of patients had recurrence of either anal fissure or symptoms like pruritus. QoL: Not assessed. Safety: Not assessed.</td>
<td>Removal of hypertrophied anal papillae and fibrous polyps should be carried on a routine basis during surgical treatment of anal fissure. This would add to the effectiveness and completeness of the procedure. The lack of a comparator group reduces ability to determine to what extent improvements may have occurred without treatment.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pruritus was not main focus of study.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jensen 1988</td>
<td>Randomised controlled trial</td>
<td>Patients with chronic pruritus ani and hypertrophied anal papillae. n=41. Denmark</td>
<td>Excision of hypertrophied anal papillae under local anaesthesia n=21. Follow up at 1 and 4 weeks after randomisation and treatment, and at 1 year</td>
<td>Expectant management n=20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Symptoms: Proctological evaluation of symptoms pre- and post-surgery. No significant effect was found. 14 (67%) of the 21 patients in the excision group were symptom free at 1 year compared to 11 (55%) of the 20 patients in the expectant management group (p=0.05). QoL: Not assessed. Safety: 8 (42%) of the patients in the excision group developed substantial pain within 1 week of treatment compared to zero of the 20 patients in the expectant management group (p=0.01).</td>
<td>Excision of hypertrophied anal papillae in people with chronic pruritus ani showed no effect at 1 year compared with effective management, and may be considered harmful due to the high rate of postoperative complications.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>This report did not include any details about the method of randomisation used or whether there were any efforts for concealment of allocation. It is also not clear whether this study was powered to detect significant differences between the groups.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Authors</td>
<td>Study Design</td>
<td>Participants</td>
<td>Intervention</td>
<td>Follow-up</td>
<td>Outcomes and Safety</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>--------------</td>
<td>--------------</td>
<td>-------------</td>
<td>-----------</td>
<td>---------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang et al. 2009</td>
<td>Case series (Conference abstract)</td>
<td>People with chronic intractable pruritus ani n=100</td>
<td>Perianal intracutaneous injection of Triamcinolone Follow up: 2 years (95% of patients were assessed at 2 years)</td>
<td>None</td>
<td>Symptoms: Outcomes and outcome measures not reported Results not reported in detail “we observed full relief of itching sensations” QoL: Not assessed Safety: Not reported</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lysy et al. 2003</td>
<td>Randomised placebo-controlled crossover trial</td>
<td>People with chronic idiopathic intractable pruritus ani n=49 Israel</td>
<td>Capsaicin cream 0.006% three times a day n=22 2 treatment phases of 4 weeks separated with 1 week washout phase Follow up: post treatment evaluation at 4 and 9 weeks After 9 weeks respondents continued in an open label study with a follow up every 2-3 months (mean 10.9 (SD 5.8) months)</td>
<td>Placebo (menthol 1%) cream n=22</td>
<td>Symptoms: Pre- and post-treatment clinical evaluation and 28-day patient symptom diaries for both 4 weeks’ treatment phases There was a significant effect for capsaicin treatment with 31 of 44 patients being symptom free (p&lt;0.0001). QoL: Not assessed Safety: ● Burning (side effect) score and duration were significantly higher following capsaicin treatment (p&lt;0.001) than with placebo ● 4 people dropped out due to intolerable burning side effects, and one due to urticaria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mentes et al. 2003</td>
<td>Case series</td>
<td>Adults with intractable idiopathic pruritus ani. n=30 Turkey</td>
<td>15 ml solution of equal volume of 2% methylene blue and 0.5% lidocaine injected intracutaneously and subcutaneously in the affected perianal area. Second injection a month later for patients (n=5) with partial response. Follow up at 24 hours for early complications, at 1 and 6 months, and then on an annual basis.</td>
<td>None</td>
<td>Symptoms: ● At 1 month, 24 (80%) were symptom free, 5 had partial remission, and 1 patient had no change. With the second injection 28 (93.3%) were symptom free. ● At 6 months, 25 (83.3%) were symptom free. ● At 1 year, 23 (76.6%) were symptom free. QoL: ● Not assessed Safety: ● No major complications were reported Other ● At 1 month, symptomatic healing was confirmed by observation of the disappearance of perianal excoration and lichenification.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Local injection of Triamcinolone is simple but very effective method to treat chronic intractable pruritus ani. The lack of a comparator group reduces ability to determine to what extent improvements may have occurred without treatment. Lack of data for outcomes and results in conference abstract.

Lack of data for outcomes and results in conference abstract.

The report did not provide any details about the concealment of allocation. This study randomised 49 patients of which 5 dropped in the first week of treatment due to side effects. The analysis does not seem to account for the drop outs.

This study showed that intradermal methylene blue injection is a safe, simple, fast and efficient method of treating intractable pruritus ani. The lack of a comparator group reduces ability to determine what extent improvements may have occurred without treatment. Inconsistent reporting of the quantity of methylene blue throughout.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Study Design</th>
<th>Participants</th>
<th>Therapeutic Approach</th>
<th>Follow-up</th>
<th>Symptoms Description</th>
<th>The treatment response was favourable in all patients. Symptoms remission was consistent with perianal skin recovery.</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miravalle et al. 2013</td>
<td>Case series (conference abstract)</td>
<td>Adults &gt;18 yrs with idiopathic pruritus ani n=24 Colorectal surgery centre Argentina</td>
<td>Therapeutic algorithm: Step 1. Hygiene and lifestyle modification Step 2. Topical hydrocortisone Step 3 Topical capsaicin  Follow up: 6 months None</td>
<td></td>
<td>Pruritus was assessed by 100 mm Visual Analogue Scale (VAS)  At 6 months, 22 (91.7%; 95% CI 73-99) were symptom free. 2 patients (8.3%; 95% CI 1-27) had partial response. QoL  Not assessed Safety  Not assessed</td>
<td>None symptoms were assessed by 100 mm Visual Analogue Scale (VAS)  At 6 months, 22 (91.7%; 95% CI 73-99) were symptom free. 2 patients (8.3%; 95% CI 1-27) had partial response. QoL  Not assessed Safety  Not assessed</td>
<td></td>
</tr>
<tr>
<td>Novak et al. 1976</td>
<td>Controlled clinical trial</td>
<td>Patients with chemically induced pruritus ani N=not reported in abstract</td>
<td>Single intravenous doses of 100, 200, or 400 mg of hydrocortisone sodium succinate and hydrocortisone sodium phosphate Placebo Aetiology  Chemical induced pruritus ani  More subjects receiving hydrocortisone sodium phosphate experienced systemic or localized adverse effects than those receiving hydrocortisone sodium succinate 16 of 18 subjects medicated with hydrocortisone sodium phosphate experienced side effects of burning and itching 1 subject of 6 treated with placebo (saline) and none in the sodium succinate group.</td>
<td></td>
<td>The side effect of burning and itching in the anorectal area is attributed to the phosphate steroid and appears to last as long as it takes to convert to cortisol.  The abstract does not discuss any other factors that could have contributed to occurrence of pruritus ani. Limited data on measures used.</td>
<td>None symptomatics were assessed by 100 mm Visual Analogue Scale (VAS)  At 6 months, 22 (91.7%; 95% CI 73-99) were symptom free. 2 patients (8.3%; 95% CI 1-27) had partial response. QoL  Not assessed Safety  Not assessed</td>
<td></td>
</tr>
<tr>
<td>Oztaz et al. 2003</td>
<td>Prospective observational study</td>
<td>People with idiopathic pruritus ani n=60 University hospital department of dermatology Turkey</td>
<td>Topical steroids (Advantan cream) twice daily for two weeks n=28 Follow up: two weeks Liquid cleanser (Protex) twice daily for two weeks n=32</td>
<td></td>
<td>Patient reported pruritus scores (0-10, 0 - no pruritus, 10 most severe pruritus)  At 2 weeks treatment was effective in 26 (92.3%) patients in the topical steroid group and in 29 (90.6%) in the liquid cleanser group. There was no statistically significant difference between the two groups, p&gt;0.05. QoL  Not assessed Safety  No side effects were detected in both groups at the end of the treatment</td>
<td>Perianal cleansing is as effective as topical corticosteroids in the treatment of idiopathic pruritus ani. Mild cleansers could be used as a safe first step treatment for controlling perianal itching.  This was a prospective observational study with a potential for allocation bias. The results were not reported in detail. The outcomes were measured subjectively. The patients were not followed up after the post treatment evaluation at 2 weeks.</td>
<td></td>
</tr>
</tbody>
</table>
### Pruritus Ani

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Participants</th>
<th>Intervention</th>
<th>Follow-up</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samalavičius et al. 2012</td>
<td>Case series</td>
<td>People with intractable idiopathic pruritus ani</td>
<td>15 ml 1% methylene blue solution (10 ml 2% methylene blue, 5 ml saline, 5 ml 2% lidocaine solution) injected intradermally in the perianal itching area</td>
<td>Follow up at 4 weeks (clinical examination) and by telephone interview at 6 and 12 months, and then on a yearly basis.</td>
<td>None</td>
</tr>
<tr>
<td>Sutherland et al. 2008</td>
<td>Case series</td>
<td>Adults with refractory idiopathic pruritus ani</td>
<td>Solution of 10 ml 1% methylene blue, 20 ml of 0.5% marcain and 1 ml 1% adrenaline and 1 ml methyl-prednisolone</td>
<td>1 intradermal injection</td>
<td>Review at 4 weeks Follow up at 8 weeks (waiting for long term follow up)</td>
</tr>
<tr>
<td>Suys 2012</td>
<td>Randomised double-blind placebo-controlled crossover trial (Letter)</td>
<td>People with resistant idiopathic pruritus ani</td>
<td>0.1% Tacrolimus ointment once daily</td>
<td>Placebo (petrolatum) once daily</td>
<td>Symptoms</td>
</tr>
</tbody>
</table>

- **Patient symptom score (1 - 5, 1 = worst) was used to measure itching severity**
- **All 10 patients were symptom free at 4 weeks after treatment**
- **At long term follow up, median 47 months (range 29-60) 8 patients reported recurrence of symptoms.**
- **QoL**
- **Not assessed**
- **Safety**
- **No severe side effects were reported. Mild side effects related to sensory cutaneous innervation were reported in all patients within the first 4 weeks.**

- **Intradermal injection of 1% methylene blue solution is associated with a positive effect on idiopathic pruritus ani in the short term (4 weeks). Long term success rate was 20%.**

**Safety**

- **Not assessed**

**QoL**

- **96% reported improvement**

**Symptoms**

- **Intensity and frequency of anal itch**
- **Significant positive effect of tacrolimus vs placebo on both itch intensity (-1.73 vs -0.005, p=0.044) and frequency (-1.71 vs 0.03, p=0.019)**
- **QoL**
- **Dermatology Life Quality Index results were positive but not significant for tacrolimus vs placebo (3.77 vs -1.04, p=0.146)**
- **Safety**
- **No side effects were reported**

- **The study design did not allow for assessment of the long term effects.**
- **This study was published as a letter so the report was very brief.**
Dermatologists or colorectal surgeons have conducted clinical studies on PA and their respective views of the anorectal anatomy and physiology are very different. The striking feature of the studies conducted by these two groups of clinicians is the seemingly different populations of patients with distinct aetiology. Clearly, patients with obvious dermatoses would be referred to a dermatologist and those with proctological issues to a colorectal surgeon. However, subpopulations of patients referred without an obvious underlying cause will be directed according to the referrer’s normal clinical practice. This suggests that the populations would continue to have an overlap, but the treatment algorithms used by dermatologists and colorectal surgeons suggest otherwise. Either there are two distinct groups of patients seen in dermatology and coloproctology or widely alternative therapies are being used to tap into anti-pruritic pathways.

### Topical and intradermal steroids

Al-Ghnaniem et al., compared hydrocortisone 1% ointment and advice with placebo and advice in a randomised crossover trial, which reported a significant (68%) reduction in severity of itching with hydrocortisone when compared with placebo[29]. However, the sample size was 11 and outcomes were measured at the end of 2-week treatment period with no long term follow up. In another prospective observational study, Öztąż et al., showed no difference in symptom control between topical steroids and a liquid cleanser, but both were said to be effective in 90% of cases[43]. Although this was a larger study with 28 patients treated with topical steroids alone and 32 patients with liquid cleanser alone, this was not randomised. Furthermore, it is unclear how treatment options were selected for individual patients. There is one case series with longer term follow up. Kang et al injected

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Year</th>
<th>Study Design</th>
<th>Population</th>
<th>Intervention</th>
<th>Follow up</th>
<th>Symptoms</th>
<th>Topical tacrolimus</th>
<th>Topical and intradermal steroids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ucak et al.</td>
<td>2013</td>
<td>Randomised placebo-controlled crossover trial</td>
<td>Adults &gt;18 yrs with persistent pruritus ani and atopic dermatitis (n=32 Turkey)</td>
<td>0.03% tacrolimus ointment twice daily for 4 weeks’ treatment/placebo 2 week washout period 4 weeks’ placebo/treatment</td>
<td>Follow up: 8 weeks after treatment completion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xie and Lan</td>
<td>2014</td>
<td>Case series (Conference abstract)</td>
<td>Adult male patients with pruritus ani (N=41 University hospital China)</td>
<td>0.1% tacrolimus ointment Duration of treatment: not reported</td>
<td>Follow up: not reported</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Symptoms
- Patient perianal itching score (0 to 3, 0=none to 3=severe); primary outcome
- There was a statistically significant decrease in itching score for the tacrolimus group compared to the placebo group at weeks 4 and 6 (p=0.001).
- At 18 weeks follow up the relapse rates were high in both groups 13 (81%) in the tacrolimus group and 11 (69%) in the placebo group.

Safety
- No significant side effects were identified

Other
- Eczema Area and Severity Index (EASI) showed significant improvement at weeks 4 and 6 (p=0.001 and p=0.002 respectively)
Triamcinolone intracutaneously in 100 patients and found 95% to have symptom relief after 2 years[38]. However, this was a conference abstract with no details of how symptom improvement was measured and this abstract was never followed up with a paper publication.

**Topical tacrolimus**

There are two randomised trials and one case series reporting the therapeutic effect of topical tacrolimus in PA[32-34]. Suys et al., performed a randomised double-blinded trial involving 22 patients with a statistically significant improvement in symptom control after 4 weeks treatment with topical tacrolimus[32]. This was published as a letter, with no long-term follow-up and provided no details of how outcomes were measured. Xei et al., published a conference abstract describing a randomised crossover study of topical tacrolimus in 16 patients[33]. The methodology was not described, but symptoms were assessed at the end of each 4-week intervention period and a further assessment 8 weeks after. They reported a statistically significant improvement in the topical tacrolimus intervention group as opposed to placebo intervention group, but actual numbers were not provided. In addition, the relapse rate of those that had symptomatic improvement at the 8 week review was 75%. The case series by Xei et al., was an investigation into the mechanism of action of topical tacrolimus in PA[34]. This conference abstract suggested a significant symptom improvement in their 41 patients, but the period of follow up was not mentioned. Although these studies reported an improvement in symptoms, the relapse rate was high and follow-up was very short. Tacrolimus is known to produce burning itch as a side effect by indirectly activating a transient receptor potential channel namely TRPV1. The therapeutic effect of tacrolimus is therefore not by inhibition of itch, but by counter-irritation. Although the evidence to support the use of this agent is limited, the risks are minor, so it can be safely trialled.

**Topical capsaicin**

Topical capsaicin cream has been used for the treatment of PA, but there has only been one study of reasonable quality. Lysy et al., performed a randomised crossover study, which showed significant improvement in PA symptoms[31]. There were 44 patients included in the study and the mean follow-up was 10.9 months. There are other case series with very small numbers which suggested capsaicin to have a therapeutic benefit. The positive results of these initial studies have not been borne out in clinical practice, which mirrors the poor results found in several randomised studies of capsaicin therapy in pain[41]. Capsaicin at higher doses desensitises the TRPV1 receptor. The doses used in the treatment of pain and itch do not desensitise the receptor at all; like tacrolimus, they probably work by counter-irritation rather than by inhibition of pruritic processing. It remains safe at this dosage, but most patient cease use of capsaicin because of the burning sensation.

**Anal tattooing**

Woloch described the first series of therapeutic methylene blue injection for PA in 1979 in 9 patients with the injection of 15 - 20 ml of 1% methylene blue with a good response in all[42]. Eusebio described this as anal tattooing by injecting 30 ml of 0.5% methylene blue[46,47]. This study reported complete relief in half of 26 patients, a partial response in 30%, and no response in 9%. The sole use of methylene blue resulted in skin necrosis in some patients. This technique has subsequently been modified to reduce the risk of skin necrosis. There are 4 studies which used a modified admixture are included in Table 1[37-40].

Botterill et al., used a mixture of 5 ml of 1% methylene blue, 15 ml of 1% Lignocaine and 100 mg of hydrocortisone on 25 patients[34]. With the first injection, 16 out of 25 were render symptom free. The 9 who were non-responders had a second injection and 6 of these patients also responded. Their median follow-up was 11 months (2 - 25 months). A case series by Samalavicius et al described a technique with admixture of 10 ml of 2% methylene blue with 5ml of 2% lignocaine and 5ml of saline[39]. They had a series of 10 patients all of whom were symptom free at 4 weeks. This study had a follow up of a median of 47 months. Over all 20% of the patients remained symptom free and a further 40% had recurrent symptoms of lesser magnitude. A further case series by Sutherland et al used a mixture of 10 ml of 1% methylene blue, 20 ml of 0.5% bupivacaine with 1:200000 adrenaline and 1 ml of methyl prednisolone[40]. The series had 49 patients of which 30 had complete resolution of symptoms after one injection. The non-responders had a second injection, 4 of which had a complete resolution of symptoms. However, these assessments were made at 8 weeks follow-up. Mentes et al., used an admixture of 15 ml of 2% methylene blue and 0.5% lignocaine (variable volume used) in 30 patients[37]. Twenty-four of them were symptom free after one injection and 5 patients with partial response received a second injection. Four of these 5 also became symptom free. At 6 month follow up 25 remained symptoms free and 23 remain symptom free at 1 year follow-up.

Methylene blue anal tattooing (Figure 2) seems to be the most effective therapeutic effect on PA symptoms of all the intervention described. However, the admixture concentration of methylene blue varies from 0.25 - 1%. The type of steroid used also varies. One study by Novak et al suggested that the injectable steroid should be a succinate rather than a phosphate, as the latter formulation produced a burning itch in itself[42]. The mechanism of action of methylene blue is by sensory neurolysis, as suggested in an electron microscopy study showing nerve-ending damage by the methylene blue. This explains the hypoesthesia induced. However, this sensory neurolysis does recover within a year, which may explain relapse of PA seen with this therapy.
Conclusion

The aim of this paper was a review of the best evidence available on the current treatment of PA. We set up to perform a systematic review, but were unable due to the heterogeneity of evidence so we performed a review instead. The methodology used in systematic reviews has been followed as closely, without being able to collate the results from different studies. The aetiology, examination and investigations for managing PA patients has not been described in detail and can be found well described elsewhere. There remains an evidence gap in the pathophysiology and treatment of PA. More research is needed, but there are so many unknowns about the nature of PA, this will be currently difficult to perform. The understanding of pruritus and pruritic processing is in its infancy and lags our knowledge of pain. Conservative therapies help with mild to moderate symptoms. Newer therapies such as tacrolimus and capsaicin have failed to live up to initial promise, although they can be effective in a few. Anal tattooing shows the greatest promise.

References

6. Rothman, S. Physiology of itching. (1941) Physiological reviews 21(2): 357-381.